Table 1.
Cell typeb | Strain | No. of MPSs | Treatment | No. (%) of: |
||||
---|---|---|---|---|---|---|---|---|
Chromatids | Isochromatid breaks and fragments | Radials | EPT-1 | EPT-2 | ||||
Con | Lex1 | 96 | NT | 1 (1.0) | 2 (2) | 0 | 0 | 0 |
WT | Lex1 | 112 | NT | 1 (0.9) | 1 (0.9) | 0 | 0 | 0 |
+/− | Lex1 | 112 | NT | 2 (1.7) | 2 (1.7) | 0 | 0 | 0 |
KS | Lex1 | 106 | NT | 3 (2.8) | 0 | 0 | 0 | 0 |
KA | Lex1 | 101 | NT | 0 | 62 (28.5) | 0 | 0 | 0 |
KR | Lex1 | 89 | NT | 7 (7.9) | 6 (6.7) | 0 | 0 | 0 |
Con | AB2.2 | 168 | NT | 2 (1.2) | 4 (2.4) | 0 | 0 | 0 |
WT | AB2.2 | 163 | NT | 3 (1.8) | 11 (6.7) | 0 | 0 | 0 |
+/− | AB2.2 | 163 | NT | 11 (6.7) | 17 (10.4) | 0 | 0 | 0 |
KS | AB2.2 | 179 | NT | 11 (5.8) | 15 (7.9) | 0 | 0 | 0 |
KA | AB2.2 | 153 | NT | 27 (17.6) | 29 (19) | 7 (4.6) | 23 (15.6) | 92 (60) |
KR | AB2.2 | 131 | NT | 17 (12.9) | 28 (21.3) | 6 (4.6) | 0 | 0 |
Con | AB2.2 | 166 | MMC | 6 (3.6) | 20 (12) | 0 | 0 | 0 |
KA | AB2.2 | 154 | MMC | 41 (26.6) | 59 (38.3) | 19 (12.3) | 24 (15.5) | 79 (51) |
KR | AB2.2 | 63 | MMC | 14 (20.6) | 30 (44.1) | 6 (8.8) | 0 | 0 |
Con | AB2.2 | 178 | CPT | 7 (3.9) | 22 (12.3) | 0 | 0 | 0 |
KA | AB2.2 | 165 | CPT | 38 (23.1) | 43 (26.2) | 4 (2.4) | 80 (46) | 32 (21) |
KR | AB2.2 | 130 | CPT | 24 (18.3) | 42 (32.0) | 1 (0.8) | 0 | 0 |
WT | AB2.2 | 132 | HU | 7 (5.3) | 35 (26.5) | 2 (1.5) | 0 | 0 |
KA | AB2.2 | 91 | HU | 33 (36.3) | 61 (67) | 7 (7.7) | 75 (82.4) | 3 (3.2) |
KR | AB2.2 | 133 | HU | 39 (29.3) | 78 (59.4) | 13 (7.7) | 2 (1.5) | 0 |
Shown is a summary of data for MPSs derived from Lex1 and AB2.2 cells. Cells were exposed to no treatment (NT) or were treated with MMC (30 nM for 16 h), CPT (50 nM for 16 h), or HU (1 mM for 2 h). The percentage of MPSs with at least one event is shown in parentheses. Note that some of the metaphase spreads have more than one event.
Con, control; +/−, MmRAD51+/−.